ArticlesAntibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine
References (16)
- et al.
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age
Lancet
(1992) - et al.
Influence of antibody affinity in the performance of different antibody assays
J Clin Immunol Method
(1984) - et al.
The importance of antibody affinity in the performance of immunoassays for antibody
J Clin Immunol Method
(1985) - et al.
Testing for neutralising potential of serum antibodies to tetanus and diphtheria
Lancet
(1992) Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events
Lancet
(1988)Immunisation against infectious disease
(1988)Immunisation against infectious disease
(1990)
Cited by (27)
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom
2021, EBioMedicineCitation Excerpt :Notification rates are dependant on the use of diagnostics, reporting and ascertainment per country and therefore do not reflect the real incidence numbers. In response to continued pertussis disease, many countries have adopted an accelerated schedule of primary series vaccinations and all western countries have implemented booster vaccinations in childhood [27,28]. In addition, some countries introduced extra aP boosters for adolescents and adult target populations, including pregnant women, military conscripts, healthcare workers, and older adults [29–34].
Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series
2020, VaccineCitation Excerpt :This observation confirms the greater immunogenicity of prime-boost conjugate schedules using the same protein at both phases [19,21]—in this case, tetanus toxoid. The safety data summarized in this report are concordant with rates of local and systemic reactions previously reported for acellular pertussis-containing vaccines and conjugate vaccines given according to this accelerated schedule [22–24]. Finally, the results of this study should be taken in the context of evolving understanding of the mechanisms of effectiveness of conjugate vaccines in general and meningococcal vaccines, in particular.
Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial
2017, VaccineCitation Excerpt :Serum values were expressed in µg/ml as the reference serum was calibrated against the international reference serum lot 89S (FDA) [25]. To detect a difference of 10% in antibody levels, 300 infants (150 from each group) needed to be included (α: 0.05, β: 0.10)[26]. Before unblinding, a statistical analysis plan was deposit with the Danish Calmette Study Data Safety and Monitoring Bard.
Diphtheria Toxoid
2017, Plotkin's VaccinesTetanus Toxoid
2017, Plotkin's VaccinesDiphtheria toxoid
2012, Vaccines: Sixth Edition